<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113156</article-id><article-id pub-id-type="publisher-id">ACM-41009</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_41247837.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  静注大剂量丙种球蛋白与溶血病新生儿坏死性小肠结肠炎发生关系的研究
  Study on the Relationship between Intravenous Injection of Large Doses of Intravenous Immunoglobulin and Necrotizing Enterocolitis in Neonates with Hemolytic Disease
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>孟兰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姜</surname><given-names>红</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛大学附属医院，山东 青岛</addr-line></aff><aff id="aff2"><addr-line>青岛大学附属青岛市海慈医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>1095</fpage><lpage>1101</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：通过对足月ABO溶血病新生儿静注大剂量丙种球蛋白后血清I-FABP、D-Lac水平的测定，探讨静注大剂量丙种球蛋白与溶血病新生儿坏死性小肠结肠炎发生的关系。方法：选择2018年12月至2019年12月我院新生儿科收治的足月ABO溶血病患儿60例，分为实验组及对照组。采用酶联免疫吸附法(ELISA)检测不同时间点血清中I-FABP、D-Lac水平，比较不同组内、组间血清I-FABP、D-Lac水平变化。结果：实验组血清I-FABP水平分别为：(1.45 &#177; 0.26) ng/ml、(3.78 &#177; 0.38) ng/ml和(3.39 &#177; 0.44) ng/ml，组内比较差异有统计学意义(P &lt; 0.05)；对照组血清I-FABP水平分别为：(1.34 &#177; 0.23) ng/ml、(1.43 &#177; 0.17) ng/ml和(1.43 &#177; 0.18) ng/ml，组内比较差异无统计学意义(P &gt; 0.05)；两组组间比较：F = 530.188, P &lt; 0.05提示差异有统计学意义，实验组血清D-Lac水平分别为(3.93 &#177; 1.0) ug/ml、(7.42 &#177; 1.1) ug/ml和(7.88 &#177; 1.1) ug/ml，组内比较差异有统计学意义(P &lt; 0.05)；对照组血清D-Lac水平分别为：(3.78 &#177; 0.75) ug/ml、(3.66 &#177; 0.66) μg/ml、(3.70 &#177; 0.85) μg/ml，组内比较差异无统计学意义(P &gt; 0.05)；两组组间比较差异有统计学意义(F = 300.0, P &lt; 0.05)。实验分析中检测时间与分组因素存在交互作用，通过简单效应的程序分析，提示差异主要与分组因素相关。结论：静注大剂量丙种球蛋白可引起肠道粘膜损伤，是溶血病新生儿NEC发生的一个高危因素。
    Objective: To investigate the relationship between high dose of Intravenous immunoglobulin and necrotizing enterocolitis in neonates with full-term hemolytic disease (ABO) by measuring the serum I-FABP and D-LAC levels after intravenous injection of high dose intravenous immunoglobulin. Methods: A total of 60 children with full-term ABO hemolytic disease admitted to the neonatal department of our hospital from December 2018 to December 2019 were selected and divided into the experimental group and the control group. Serum I-FABP and D-LAC levels were detected by enzyme-linked immunosorbent assay (ELISA) at different time points, and the changes of serum I-FABP and D-LAC levels in different groups and between groups were compared. Results: The levels of serum I-FABP in the experimental group were (1.45 &#177; 0.26) ng/ml, (3.78 &#177; 0.38) ng/ml and (3.39 &#177; 0.44) ng/ml, respectively, with statistical significance within the groups (P &lt; 0.05). Serum I-FABP levels in the control group were (1.34 &#177; 0.23) ng/ml, (1.43 &#177; 0.17) ng/ml and (1.43 &#177; 0.18) ng/ml, respectively, and there was no significant difference between the two groups (P &gt; 0.05). Comparison between the two groups: F = 530.188, P &lt; 0.05 indicated a statistically significant difference. Serum D-LAC levels of the experimental group were (3.93 &#177; 1.0) ug/ml, (7.42 &#177; 1.1) ug/ml and (7.88 &#177; 1.1) ug/ml, respectively, and the difference within the groups was statistically significant (P &lt; 0.05). The serum D-LAC levels in the control group were (3.78 &#177; 0.75) ug/ml, (3.66 &#177; 0.66) μg/ml and (3.70 &#177; 0.85) μg/ml, respectively, and there was no significant difference between the two groups (P &gt; 0.05). The difference between the two groups was statistically significant (F = 300.0, P &lt; 0.05). In the experimental analysis, there was an interaction between detection time and grouping factors. Through the program analysis of simple effect, it was suggested that the difference was mainly related to grouping factors. Conclusions: Intravenous large doses of immunoglobulin can cause intestinal mucosal damage, which is a high risk factor for NEC in neonates with hemolytic disease. 
  
 
</p></abstract><kwd-group><kwd>新生儿溶血病，静注丙种球蛋白，肠脂肪酸结合蛋白，D-乳酸，
坏死性小肠结肠炎, Hemolytic Disease of Newborn</kwd><kwd> Intravenous Immunoglobulin (IVIG)</kwd><kwd> Intestinal Fatty Acid-Binding Protein (I-FABP)</kwd><kwd> D-Lactate (D-Lac)</kwd><kwd> Necrotizing Enterocolitis (NEC)</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：通过对足月ABO溶血病新生儿静注大剂量丙种球蛋白后血清I-FABP、D-Lac水平的测定，探讨静注大剂量丙种球蛋白与溶血病新生儿坏死性小肠结肠炎发生的关系。方法：选择2018年12月至2019年12月我院新生儿科收治的足月ABO溶血病患儿60例，分为实验组及对照组。采用酶联免疫吸附法(ELISA)检测不同时间点血清中I-FABP、D-Lac水平，比较不同组内、组间血清I-FABP、D-Lac水平变化。结果：实验组血清I-FABP水平分别为：(1.45 &#177; 0.26) ng/ml、(3.78 &#177; 0.38) ng/ml和(3.39 &#177; 0.44) ng/ml，组内比较差异有统计学意义(P &lt; 0.05)；对照组血清I-FABP水平分别为：(1.34 &#177; 0.23) ng/ml、(1.43 &#177; 0.17) ng/ml和(1.43 &#177; 0.18) ng/ml，组内比较差异无统计学意义(P &gt; 0.05)；两组组间比较：F = 530.188, P &lt; 0.05提示差异有统计学意义，实验组血清D-Lac水平分别为(3.93 &#177; 1.0) ug/ml、(7.42 &#177; 1.1) ug/ml和(7.88 &#177; 1.1) ug/ml，组内比较差异有统计学意义(P &lt; 0.05)；对照组血清D-Lac水平分别为：(3.78 &#177; 0.75) ug/ml、(3.66 &#177; 0.66) μg/ml、(3.70 &#177; 0.85) μg/ml，组内比较差异无统计学意义(P &gt; 0.05)；两组组间比较差异有统计学意义(F = 300.0, P &lt; 0.05)。实验分析中检测时间与分组因素存在交互作用，通过简单效应的程序分析，提示差异主要与分组因素相关。结论：静注大剂量丙种球蛋白可引起肠道粘膜损伤，是溶血病新生儿NEC发生的一个高危因素。</p></sec><sec id="s2"><title>关键词</title><p>新生儿溶血病，静注丙种球蛋白，肠脂肪酸结合蛋白，D-乳酸， 坏死性小肠结肠炎</p></sec><sec id="s3"><title>Study on the Relationship between Intravenous Injection of Large Doses of Intravenous Immunoglobulin and Necrotizing Enterocolitis in Neonates with Hemolytic Disease<sup> </sup></title><p>Menglan Wang<sup>1</sup>, Hong Jiang<sup>2*</sup></p><p><sup>1</sup>Qingdao Haici Hospital Affiliated to Qingdao University, Qingdao Shandong</p><p><sup>2</sup>The<sup> </sup>Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/39-1572005x5_hanspub.png" /></p><p>Received: Feb. 16<sup>th</sup>, 2021; accepted: Mar. 5<sup>th</sup>, 2021; published: Mar. 18<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/39-1572005x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the relationship between high dose of Intravenous immunoglobulin and necrotizing enterocolitis in neonates with full-term hemolytic disease (ABO) by measuring the serum I-FABP and D-LAC levels after intravenous injection of high dose intravenous immunoglobulin. Methods: A total of 60 children with full-term ABO hemolytic disease admitted to the neonatal department of our hospital from December 2018 to December 2019 were selected and divided into the experimental group and the control group. Serum I-FABP and D-LAC levels were detected by enzyme-linked immunosorbent assay (ELISA) at different time points, and the changes of serum I-FABP and D-LAC levels in different groups and between groups were compared. Results: The levels of serum I-FABP in the experimental group were (1.45 &#177; 0.26) ng/ml, (3.78 &#177; 0.38) ng/ml and (3.39 &#177; 0.44) ng/ml, respectively, with statistical significance within the groups (P &lt; 0.05). Serum I-FABP levels in the control group were (1.34 &#177; 0.23) ng/ml, (1.43 &#177; 0.17) ng/ml and (1.43 &#177; 0.18) ng/ml, respectively, and there was no significant difference between the two groups (P &gt; 0.05). Comparison between the two groups: F = 530.188, P &lt; 0.05 indicated a statistically significant difference. Serum D-LAC levels of the experimental group were (3.93 &#177; 1.0) ug/ml, (7.42 &#177; 1.1) ug/ml and (7.88 &#177; 1.1) ug/ml, respectively, and the difference within the groups was statistically significant (P &lt; 0.05). The serum D-LAC levels in the control group were (3.78 &#177; 0.75) ug/ml, (3.66 &#177; 0.66) μg/ml and (3.70 &#177; 0.85) μg/ml, respectively, and there was no significant difference between the two groups (P &gt; 0.05). The difference between the two groups was statistically significant (F = 300.0, P &lt; 0.05). In the experimental analysis, there was an interaction between detection time and grouping factors. Through the program analysis of simple effect, it was suggested that the difference was mainly related to grouping factors. Conclusions: Intravenous large doses of immunoglobulin can cause intestinal mucosal damage, which is a high risk factor for NEC in neonates with hemolytic disease.</p><p>Keywords:Hemolytic Disease of Newborn, Intravenous Immunoglobulin (IVIG), Intestinal Fatty Acid-Binding Protein (I-FABP), D-Lactate (D-Lac), Necrotizing Enterocolitis (NEC)</p><disp-formula id="hanspub.41009-formula13"><graphic xlink:href="//html.hanspub.org/file/39-1572005x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/39-1572005x8_hanspub.png" /> <img src="//html.hanspub.org/file/39-1572005x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 前言</title><p>新生儿溶血病是早期新生儿高胆红素血症和胆红素脑病的常见原因之一，循证医学 [<xref ref-type="bibr" rid="hanspub.41009-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.41009-ref2">2</xref>] 表明，早期静脉应用大剂量丙种球蛋白(IVIG)可有效阻断溶血，显著降低胆红素脑病的发生，减少换血的需求，且不增加并发症的发生 [<xref ref-type="bibr" rid="hanspub.41009-ref3">3</xref>]，因此IVIG被推荐用于ABO溶血性疾病的治疗 [<xref ref-type="bibr" rid="hanspub.41009-ref4">4</xref>]。有临床回归分析表明，静注大剂量丙种球蛋白可使溶血病新生儿坏死性小肠结肠炎(NEC)的发生率增加 [<xref ref-type="bibr" rid="hanspub.41009-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.41009-ref6">6</xref>]；本研究主要以足月ABO溶血病新生儿为研究对象，观察应用IVIG后血清I-FABP和D-LAC水平的变化，探讨静注大剂量丙种球蛋白与溶血病新生儿NEC发生的关系。</p></sec><sec id="s6"><title>2. 对象与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>病例来源于2018.12~2019.12年我院新生儿科收治的足月ABO溶血病新生儿254例。ABO溶血病诊断标准 [<xref ref-type="bibr" rid="hanspub.41009-ref7">7</xref>]：① 新生儿早期出现黄疸，且进行性加重；② 母子ABO血型不和；③ 新生儿的外周静脉血清免疫学检查，显示直接抗人球蛋白实验和(或)抗体释放实验阳性，且未伴有其他疾病。目前已知的可以引起足月新生儿发生NEC的危险因素为：生后窒息、败血症、先天性心脏病，先天性肠道畸形、宫内生长发育迟缓、呼吸窘迫综合征、机械通气、孕妇患有高血压性疾病等 [<xref ref-type="bibr" rid="hanspub.41009-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.41009-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.41009-ref10">10</xref>]。因此入组新生儿需符合以上ABO溶血病诊断标准，且排除以上可能诱发足月儿发生NEC的危险因素，最终被纳入新生儿共计60例。按是否应用丙种球蛋白分为实验组(30例)与对照组(30例)。</p></sec><sec id="s6_2"><title>2.2. 资料收集</title><p>所采集的信息包括：1) 患儿基本信息：胎龄、性别、入院日龄、分娩方式、出生体重、喂养方式，生后黄疸出现时间；2) 患儿实验室检查结果：血清最高总胆红素数值；3) 合并症：母亲妊娠期糖尿病。两组患儿一般人口学特征见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> General demographic characteristics of the newbor</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >应用IVIG组(n = 30)</th><th align="center" valign="middle" >未用IVIG组(n = 30)</th><th align="center" valign="middle" >t/x<sup>2</sup>值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >女性[例(%)]</td><td align="center" valign="middle" >16 (53.33)</td><td align="center" valign="middle" >15 (50)</td><td align="center" valign="middle" >0.06</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >胎龄(周)</td><td align="center" valign="middle" >39.1 &#177; 1.1</td><td align="center" valign="middle" >39.1 &#177; 1.2</td><td align="center" valign="middle" >0.25</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >出生体重(kg)</td><td align="center" valign="middle" >3.51 &#177; 0.45</td><td align="center" valign="middle" >3.5 &#177; 0.35</td><td align="center" valign="middle" >0.16</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >剖宫产[例(%)]</td><td align="center" valign="middle" >12 (40)</td><td align="center" valign="middle" >11 (36.7)</td><td align="center" valign="middle" >0.07</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >母乳喂养[例(%)]</td><td align="center" valign="middle" >27 (90)</td><td align="center" valign="middle" >25 (83.3)</td><td align="center" valign="middle" >0.65</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >黄疸出现时间(h)</td><td align="center" valign="middle" >14.07 &#177; 5.1</td><td align="center" valign="middle" >15.85 &#177; 3.96</td><td align="center" valign="middle" >−1.5</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >血总胆红素值(umol/L)</td><td align="center" valign="middle" >257.8 &#177; 33.9</td><td align="center" valign="middle" >268.2 &#177; 23.5</td><td align="center" valign="middle" >−1.37</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >妊娠期糖尿病[例(%)]</td><td align="center" valign="middle" >6 (20)</td><td align="center" valign="middle" >8 (23.33)</td><td align="center" valign="middle" >0.23</td><td align="center" valign="middle" >&gt;0.05</td></tr></tbody></table></table-wrap><p>表1. 患儿一般人口学特征</p></sec><sec id="s6_3"><title>2.3. 方法</title><sec id="s6_3_1"><title>2.3.1. 治疗方法</title><p>两组患儿均采用基础治疗，包括蓝光照射、鲁米那5 mg/(kg∙d)口服，口服益生菌等综合退黄措施，当达同日龄、同胎龄组光疗失败且未达换血标准时，实验组加用IVIG，按每次0.5~1 g/kg，4 h内均匀输入，输注1次。治疗期间密切观察黄疸进展及临床症状，如若有NEC临床表现，诊断参照NEC修正Bell分期标准 [<xref ref-type="bibr" rid="hanspub.41009-ref11">11</xref>]，一旦达到换血指征，即给予换血治疗。在治疗前患者已得到其监护人的知情同意并且经伦理委员会批准。</p></sec><sec id="s6_3_2"><title>2.3.2. 样本采集</title><p>实验组：输注丙球前、输注丙球后(0~24 h, 24~48 h)；对照组在相应的采血日龄留取血样标本，分别留取静脉血2 ml，室温放置2小时或4℃冰箱过夜保存，4000 r/min离心10 min，吸取上层血清−80℃保存，统一检测。</p></sec><sec id="s6_3_3"><title>2.3.3. 实验方法</title><p>血清I-FABP、D-LAC检测使用ELISA法，实验严格按照试剂盒说明进行标准品的稀释、加样、配洗涤液、洗涤、显色、终止，最后使用酶标仪测定各孔OD值，根据标准品浓度及对应的OD值计算出标准曲线的回归方程，再根据样品的OD值在回归方程上计算出对应的IFABP、D-LAC的浓度(计算公式：I-FABP y = 0.0955x + 0.0422、R<sup>2</sup> = 0.9946；D-Lac y = 0.0011x + 0.26、R<sup>2</sup> = 0.9695)。</p></sec></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>数据分析采用SPSS20.0软件进行，计量资料服从正态分布时用均数 &#177; 标准差( X &#175; &#177; S)表示，数据比较采用(独立样本) t检验，多组数据间比较采用两因素重复测量数据方差分析；计数资料以率(%)表示，定性资料组间比较采用X<sup>2</sup>检验。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 患儿一般情况</title><p>病例组与对照组患儿胎龄、体重、采样日龄、总胆红素数值等指标差异均无统计学意义(均P &gt; 0.05)，见表1。</p></sec><sec id="s7_2"><title>3.2. 两组患儿血清I-FABP、D-Lac水平比较</title><p>在时间点一致、不同的处理方式的情况下：两组实验前血清I-FABP、D-Lac水平无差异；试验后血清I-FABP、D-Lac水平存在差异，提示静注丙种球蛋白可以引起肠道损伤，且损伤原因主要为分组处理因素不同所致。见表2、表3。</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Serum I-FABP levels before and after the experiment ( X &#175; &#177; S) (ng/ml</title></caption><table-wrap id="2_1"><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"   rowspan="2"  >分组</th><th align="center" valign="middle"  colspan="5"  >输注丙球前后</th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle"  colspan="2"  >IVIG前</td><td align="center" valign="middle" >IVIG后(0~24 h)</td><td align="center" valign="middle" >IVIG后(24~48 h)</td><td align="center" valign="middle"  colspan="2"  ></td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle"  colspan="2"  >1.34 &#177; 0.23</td><td align="center" valign="middle"  colspan="2"  >1.43 &#177; 0.17</td><td align="center" valign="middle" >1.43 &#177; 0.18</td><td align="center" valign="middle"  colspan="2"  ></td></tr><tr><td align="center" valign="middle" >实验组</td><td align="center" valign="middle"  colspan="2"  >1.45 &#177; 0.26</td><td align="center" valign="middle"  colspan="2"  >3.78 &#177; 0.38</td><td align="center" valign="middle" >3.39 &#177; 0.44</td><td align="center" valign="middle"  colspan="2"  ></td></tr><tr><td align="center" valign="middle" >SUM</td><td align="center" valign="middle"  colspan="2"  >1.39 &#177; 0.25</td><td align="center" valign="middle"  colspan="2"  >2.60 &#177; 1.22</td><td align="center" valign="middle" >2.41 &#177; 1.04</td><td align="center" valign="middle"  colspan="2"  >(F = 685.98*, P &lt; 0.05*)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="2_2"><table><tbody><thead><tr><th align="center" valign="middle" >t</th><th align="center" valign="middle" >−1.766</th><th align="center" valign="middle" >−30.98</th><th align="center" valign="middle" >−22.68</th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.083</td><td align="center" valign="middle" >P &lt; 0.05</td><td align="center" valign="middle" >P &lt; 0.05</td><td align="center" valign="middle" >(F = 530.188#, P &lt; 0.05#)</td></tr></tbody></table></table-wrap></table-wrap-group><p>表2. 实验前后血清I-FABP水平( X &#175; &#177; S)(ng/ml)</p><p>*主效应的F统计量和P值；#交互效应的F统计量和P值。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Serum D-LAC levels before and after the experiment ( X &#175; &#177; S) (ug/ml</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"   rowspan="2"  >分组</th><th align="center" valign="middle"  colspan="3"  >输注丙球前后</th><th align="center" valign="middle"  colspan="2"  ></th></tr></thead><tr><td align="center" valign="middle" >IVIG前</td><td align="center" valign="middle" >IVIG后(0~24 h)</td><td align="center" valign="middle" >IVIG后(24~48 h)</td><td align="center" valign="middle"  colspan="2"  ></td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle"  colspan="2"  >3.78 &#177; 0.75</td><td align="center" valign="middle" >3.66 &#177; 0.66</td><td align="center" valign="middle"  colspan="2"  >3.70 &#177; 0.85</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >实验组</td><td align="center" valign="middle"  colspan="2"  >3.93 &#177; 1.0</td><td align="center" valign="middle" >7.42 &#177; 1.10</td><td align="center" valign="middle"  colspan="2"  >7.88 &#177; 1.10</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >SUM</td><td align="center" valign="middle"  colspan="2"  >3.86 &#177; 0.88</td><td align="center" valign="middle" >5.54 &#177; 2.10</td><td align="center" valign="middle"  colspan="2"  >5.79 &#177; 2.32</td><td align="center" valign="middle" >(F = 89.61*, P &lt; 0.05*)</td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle"  colspan="2"  >−6.23</td><td align="center" valign="middle" >−16.06</td><td align="center" valign="middle"  colspan="2"  >−16.44</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle"  colspan="2"  >0.536</td><td align="center" valign="middle" >P &lt; 0.05</td><td align="center" valign="middle"  colspan="2"  >P &lt; 0.05</td><td align="center" valign="middle" >(F = 99.67#, P &lt; 0.05#)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表3. 实验前后血清D-LAC水平( X &#175; &#177; S) (ug/ml)</p><p>*主效应的F统计量和P值；<sup>#</sup>交互效应的F统计量和P值。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>新生儿溶血病(HDFN)是因母、子血型不合引起的同族免疫性溶血，其中以ABO血型不合最常见；是新生儿早期高胆红素血症的主要原因之一，严重可引起急性胆红素脑病或核黄疸 [<xref ref-type="bibr" rid="hanspub.41009-ref11">11</xref>]。光疗是HDFN治疗的最常见最基本方法，当光疗治疗有限时通过使用大剂量IVIG，可以减轻溶血病的严重程度，降低换血的几率。但是，近年来，有使用大剂量IVIG治疗同族免疫性血小板减少症及足月儿和早产儿使用IVIG治疗ABO溶血病后发生NEC的报道 [<xref ref-type="bibr" rid="hanspub.41009-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.41009-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.41009-ref14">14</xref>]。Figueras-Aloy等 [<xref ref-type="bibr" rid="hanspub.41009-ref6">6</xref>] 的回顾性研究显示，IVIG是溶血病患儿发生NEC的独立危险因素(OR: 31.66, 95% CI: 3.25~308.57)。目前关于ABO溶血病患儿输注IVIG后发生NEC的原因尚不清楚。</p><p>NEC由多种因素引起，早期临床表现不典型，病情易快速进展，导致早期诊断困难，病死率高，因此我们迫切需求可以用于早期发现、具有高度敏感性和特异性的生化指标。研究证实肠道脂肪酸结合蛋白(I-FABP)和D-乳酸(D-Lac)是早期肠道缺血损伤的敏感指标，且在疾病早期即可明显升高，并与肠道损伤的程度正相关 [<xref ref-type="bibr" rid="hanspub.41009-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.41009-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.41009-ref17">17</xref>]。其中I-FABP特异性表达于回肠的黏膜绒毛上皮细胞(易缺血损伤部位)，生理条件下其在外周循环中表达量很低，当黏膜损伤后，蛋白质迅速释放到血液中 [<xref ref-type="bibr" rid="hanspub.41009-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.41009-ref19">19</xref>]。在最近的一项包括9项研究的荟萃分析中，Sun等 [<xref ref-type="bibr" rid="hanspub.41009-ref20">20</xref>] 计算出I-FABP诊断急性肠缺血的AUC为0.86 (95% CI: 0.83~0.89)，合并的敏感性和特异性分别为0.8 (95% CI: 0.72~0.86)和0.85 (95% CI: 0.73~0.93)；D-Lac主要是由肠道细菌代谢产生，人体内细胞代谢产生的D-Lac的浓度通常很低，在肠缺血引起的粘膜完整性的改变时，可导致肠道细菌异位、代谢产生增加 [<xref ref-type="bibr" rid="hanspub.41009-ref21">21</xref>]。在Treskes等人 [<xref ref-type="bibr" rid="hanspub.41009-ref22">22</xref>] 的荟萃分析(包括6项研究)中，D-Lac诊断急性肠系膜缺血的综合敏感性和特异性分别为0.72 (95% CI: 0.59~0.82)和0.74 (95% CI: 0.69~0.79)。</p><p>本实验通过检测足月ABO溶血病新生儿输注丙球前后血清中I-FABP及D-Lac水平变化发现：实验组血清I-FABP水平分别为：(1.45 &#177; 0.26) ng/ml、(3.78 &#177; 0.38) ng/ml和(3.39 &#177; 0.44) ng/ml，组内比较差异有统计学意义(P &lt; 0.05)；对照组血浆I-FABP水平分别为：(1.34 &#177; 0.23) ng/ml、(1.43 &#177; 0.17) ng/ml和(1.43 &#177; 0.18) ng/ml，组内比较差异无统计学意义(P &gt; 0.05)；两组组间比较：F = 530.188，P &lt; 0.05提示差异有统计学意义。实验组血清D-Lac水平分别为(3.93 &#177; 1.0) ug/ml、(7.42 &#177; 1.1) μg/L和(7.88 &#177; 1.1) ug/ml，组内比较差异有统计学意义(P &lt; 0.05)；对照组血清D-Lac水平分别为：(3.78 &#177; 0.75) ug/ml、(3.66 &#177; 0.66) ug/ml、(3.70 &#177; 0.85) ug/ml，组内比较差异无统计学意义(P &gt; 0.05)；两组组间比较差异有统计学意义(F = 300.0, P &lt; 0.05)，且在数据分析过程中发现：检测时间与分组因素存在交互作用，通过简单效应的程序分析，提示差异主要与分组因素相关。结论：静注大剂量丙种球蛋白可使足月ABO溶血病新生儿血清I-FABP、D-Lac水平升高，提示IVIG可引起肠道粘膜损伤，是溶血病新生儿NEC发生的一个高危因素。</p><p>本实验因病例有限，可能存在实验偏差，为更严谨验证本实验可靠性，可进一步扩大实验样本、综合临床表现及实验数据进一步验证实验。</p></sec><sec id="s9"><title>文章引用</title><p>王孟兰,姜 红. 静注大剂量丙种球蛋白与溶血病新生儿坏死性小肠结肠炎发生关系的研究Study on the Relationship between Intravenous Injection of Large Doses of Intravenous Immunoglobulin and Necrotizing Enterocolitis in Neonates with Hemolytic Disease[J]. 临床医学进展, 2021, 11(03): 1095-1101. https://doi.org/10.12677/ACM.2021.113156</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41009-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Gottstein, R. and Cooke, R.W. (2003) Systematic Review of Intravenous Immunoglobulin in Haemolytic Disease of the Newborn. ADC Fetal &amp; Neonatal Edition, 88, F6-F10. &lt;br&gt;https://doi.org/10.1136/fn.88.1.F6</mixed-citation></ref><ref id="hanspub.41009-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Louis, D., More, K., Oberoi, S. and Shah, P.S. (2014) Intravenous Immunoglobulin in Isoimmune Haemolytic Disease of Newborn: An Updated Systematic Review and Meta-Analysis. ADC Fetal &amp; Neonatal Edition, 99, F325-F331.  
&lt;br&gt;https://doi.org/10.1136/archdischild-2013-304878</mixed-citation></ref><ref id="hanspub.41009-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Li, Z., Wang, J. and Chen, C. (2010) Meta Analysis of the Effect of Immunoglobulin Infusion on Neonatal Isoimmune Hemolytic Disease Caused by Blood Group Incompatibility. Chinese Journal of Pediatrics, 48, 656-660.</mixed-citation></ref><ref id="hanspub.41009-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">杜立中, 马晓路. 新生儿高胆红素血症诊断和治疗专家共识[J]. 中华儿志, 2014, 52(10): 745-748.</mixed-citation></ref><ref id="hanspub.41009-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">胡玉莲, 夏世文. 新生儿ABO溶血病静脉用大剂量丙种球蛋白与坏死性小肠结肠炎的关系[J]. 中国新生儿科杂志, 2012(5): 34-37.</mixed-citation></ref><ref id="hanspub.41009-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Figueras-Aloy, J., Rodríguez-Miguélez, J.M., Iriondo-Sanz, M., Salvia-Roiges, M.D., Botet-Mussons, F. and Carbonell-Estrany, X. (2010) Intravenous Immunoglobulin and Necrotizing Enterocolitis in Newborns with Hemolytic Disease. Pediatrics, 125, 139-144. &lt;br&gt;https://doi.org/10.1542/peds.2009-0676</mixed-citation></ref><ref id="hanspub.41009-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">王卫平, 孙锟, 常立文. 儿科学[M]. 第9版. 北京: 人民卫生出版社, 2018.</mixed-citation></ref><ref id="hanspub.41009-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">杜桂莲, 许艳, 许玲. 足月新生儿坏死性小肠结肠炎发生特征及危险因素分析[J]. 中国现代药物应用, 2017, 11(9): 22-24.</mixed-citation></ref><ref id="hanspub.41009-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">曹立园. 64例足月新生儿坏死性小肠结肠炎高危因素临床分析[D]: [硕士学位论文]. 长春: 吉林大学, 2015.</mixed-citation></ref><ref id="hanspub.41009-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">曾德峰, 谭忠友. 新生儿坏死性小肠结肠炎的高危因素及外科治疗预后影响因素的研究[J]. 重庆医科大学学报, 2017, 42(3): 361-364.</mixed-citation></ref><ref id="hanspub.41009-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">邵肖梅, 叶鸿瑁, 丘小汕. 实用新生儿学[M]. 第5版. 北京: 人民卫生出版社, 2019: 764-769.</mixed-citation></ref><ref id="hanspub.41009-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Navarro, M., Negre, S., Matoses, M.L., et al. (2009) Necrotizing Enterocolitis Following the Use of Intravenous Immunoglobulin for Haemolytic Disease of the Newborn. Acta Paediatrica, 98, 1214-1217.  
&lt;br&gt;https://doi.org/10.1111/j.1651-2227.2009.01279.x</mixed-citation></ref><ref id="hanspub.41009-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">毛劲. 新生儿ABO型溶血应用大剂量静脉丙种球蛋白治疗导致坏死性小肠结肠炎的调查研究[J]. 临床和实验医学杂志, 2015, 14(23): 1997-2000.</mixed-citation></ref><ref id="hanspub.41009-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Krishnan, L. and Pathare, A. (2011) Necrotizing Enterocolitis in a Term Neonate Following Intravenous Immunoglobulin Therapy. Indian Journal of Pediatrics, 78, 743-744. &lt;br&gt;https://doi.org/10.1007/s12098-010-0334-4</mixed-citation></ref><ref id="hanspub.41009-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Schellekens, D.H., Grootjans, J., Dello, S.A., et al. (2014) Plasma Intestinal Fatty Acid Binding Protein Levels Correlate with Morphologic Epithelial Intestinal Damage in a Human Translational Ischemia-Reperfusion Model. Journal of Clinical Gastroenterology, 48, 253-260. &lt;br&gt;https://doi.org/10.1097/MCG.0b013e3182a87e3e</mixed-citation></ref><ref id="hanspub.41009-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">皇甫春荣, 李平, 田云粉. 肠型脂肪酸结合蛋白检测在足月新生儿坏死性小肠炎中的临床意义[J]. 中国当代儿科杂志, 2014, 16(11): 1125-1128.</mixed-citation></ref><ref id="hanspub.41009-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">杨秀钦. 肠型脂肪酸结合蛋白与D-乳酸在新生儿坏死性小肠结肠炎早期诊断中的价值探讨[D]: [硕士学位论文]. 福州: 福建医科大学, 2015.</mixed-citation></ref><ref id="hanspub.41009-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Piton, G. and Capellier, G. (2016) Biomarkers of Gut Barrier Failure in the ICU. Current Opinion in Critical Care, 22, 152-160. &lt;br&gt;https://doi.org/10.1097/MCC.0000000000000283</mixed-citation></ref><ref id="hanspub.41009-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Sekino, M., Funaoka, H., Sato, S., et al. (2017) Intestinal Fatty Acid-Binding Protein Level as a Predictor of 28-Day Mortality and Bowel Ischemia Inpatients with Septic Shock: A Preliminary Study. Journal of Critical Care, 42, 92-100.  
&lt;br&gt;https://doi.org/10.1016/j.jcrc.2017.07.012</mixed-citation></ref><ref id="hanspub.41009-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Sun, D.L., Cen, Y.Y., Li, S.M., et al. (2016) Accuracy of the Serum Intestinal Fatty-Acid Binding Protein for Diagnosis of Acute Intestinal Ischemia: A Meta-Analysis. Scientific Reports, 6, Article No. 34371.  
&lt;br&gt;https://doi.org/10.1038/srep34371</mixed-citation></ref><ref id="hanspub.41009-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Ewaschuk, J.B., Naylor, J.M. and Zello, G.A. (2005) D-Lactate in Human and Ruminant Metabolism. The Journal of Nutrition, 135, 1619-1625. &lt;br&gt;https://doi.org/10.1093/jn/135.7.1619</mixed-citation></ref><ref id="hanspub.41009-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Treskes, N., Persoon, A.M. and van Zanten, A.R.H. (2017) Diagnostic Accuracy of Novel Serological Biomarkers to Detect Acute Mesenteric Ischemia: A Systematic Review and Meta-Analysis. Internal and Emergency Medicine, 12, 821-836. &lt;br&gt;https://doi.org/10.1007/s11739-017-1668-y</mixed-citation></ref></ref-list></back></article>